IDEAYA Biosciences, Inc.

IDYASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1676725

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$23.4M	$50.9M	$27.9M	$19.5M	$0.00
Research and Development Expense	$129.5M	$89.5M	$58.2M	$39.7M	$34.3M
Operating Expenses	$157.8M	$113.4M	$78.2M	$54.9M	$44.3M
Operating Income (Loss)	-$134.4M	-$62.5M	-$50.3M	-$35.3M	-$44.3M
Nonoperating Income (Expense)	$21.5M	$3.8M	$506.0K	$849.0K	$2.3M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$113.0M	-$58.7M	-$49.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$649.3M	$388.0M	$381.3M	$298.3M
Assets, Current	$689.7M	$532.6M	$370.5M	$251.0M	$288.6M
Cash and Cash Equivalents, at Carrying Value	$157.0M	$68.6M	$92.0M	$72.0M	$34.1M
Liabilities	$64.9M	$28.2M	$38.5M	$79.8M	$100.0M
Liabilities, Current	$46.1M	$27.1M	$31.7M	$45.2M	$38.6M
Accounts Payable, Current	$15.4M	$6.6M	$4.3M	$2.1M	$953.0K
Stockholders' Equity Attributable to Parent	$349.5M	$301.5M	$198.3M	$100.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$115.2M	-$87.2M	-$55.8M	$55.5M	-$39.3M
Net Cash Provided by (Used in) Investing Activities	-$158.5M	-$33.4M	-$69.7M	-$146.2M	$2.3M
Net Cash Provided by (Used in) Financing Activities	$362.7M	$97.2M	$145.5M	$128.8M	$50.6M
Payments to Acquire Property, Plant, and Equipment	$2.4M	$3.4M	$2.6M	$493.0K	$1.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)